Literature DB >> 23184269

Posterior reversible leukoencephalopathy syndrome presenting with global cerebral edema and herniation.

Vivien H Lee1, Richard E Temes, Sayona John, James J Conners, Thomas Bleck, Shyam Prabhakaran.   

Abstract

BACKGROUND: We report a case of global cerebral edema and herniation due to Posterior Reversible Leukoencephalopathy Syndrome (PRES).
METHODS: Case report.
RESULTS: A 37-year-old healthy female developed persistent severe occipital headache, and after 1 month of persistent headache, developed an episode of loss of consciousness. CT brain showed diffuse cerebral edema and effacement of the sulci and basal cisterns. Her initial neurological examination was nonfocal but with severe headache. Overnight, she acutely became unresponsive with fixed dilated pupils, tachycardia, and hypertension. She was intubated and treated with hypertonic saline and mannitol with improvement in her clinical status. Intracranial Pressure (ICP) monitor showed elevated ICPs to 37 mmHg which responded to mannitol. MRI brain showed diffuse vasogenic edema predominantly in the white matter without enhancement. Cerebral angiogram was unremarkable. Cerebrospinal fluid including infectious work-up was negative. With supportive care, her mental status improved. On her 3 month follow-up visit, she was asymptomatic and had returned to work. Repeat MRI brain at 3 months showed persistent white matter changes that subsequently resolved at 9 months.
CONCLUSIONS: Although PRES is typically considered to have a benign clinical course, clinician should be aware that severe cases can present with global cerebral edema and associated complications including intracranial hypertension and herniation.

Entities:  

Mesh:

Year:  2013        PMID: 23184269     DOI: 10.1007/s12028-012-9798-6

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  6 in total

Review 1.  Reversible obstructive hydrocephalus from hypertensive encephalopathy.

Authors:  Abhay Kumar; Salah G Keyrouz; Jon T Willie; Rajat Dhar
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

2.  Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features.

Authors:  H M Hefzy; W S Bartynski; J F Boardman; D Lacomis
Journal:  AJNR Am J Neuroradiol       Date:  2009-04-22       Impact factor: 3.825

3.  Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome.

Authors:  O S Kozak; E F M Wijdicks; E M Manno; J T Miley; A A Rabinstein
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

4.  Posterior reversible encephalopathy syndrome associated with hemorrhage.

Authors:  Rosalyn M Aranas; Shyam Prabhakaran; Vivien H Lee
Journal:  Neurocrit Care       Date:  2009-02-19       Impact factor: 3.210

5.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

6.  Clinical spectrum of reversible posterior leukoencephalopathy syndrome.

Authors:  Vivien H Lee; Eelco F M Wijdicks; Edward M Manno; Alejandro A Rabinstein
Journal:  Arch Neurol       Date:  2008-02
  6 in total
  3 in total

1.  Refractory intracranial hypertension in posterior reversible encephalopathy syndrome.

Authors:  Alberto Facchini; Sandra Magnoni; Vittorio Civelli; Fabio Triulzi; Mario Nosotti; Nino Stocchetti
Journal:  Neurocrit Care       Date:  2013-12       Impact factor: 3.210

Review 2.  Posterior reversible encephalopathy syndrome in the emergency department: case series and literature review.

Authors:  Ryan J Thompson; Brian Sharp; Jeffery Pothof; Azita Hamedani
Journal:  West J Emerg Med       Date:  2015-01-05

Review 3.  Secondary White Matter Injury and Therapeutic Targets After Subarachnoid Hemorrhage.

Authors:  Xufang Ru; Ling Gao; Jiru Zhou; Qiang Li; Shilun Zuo; Yujie Chen; Zhi Liu; Hua Feng
Journal:  Front Neurol       Date:  2021-07-15       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.